![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
The arrangement, if consummated, would relate to the development and commercialization of PRX–110, or alidornase alfa, for the treatment of Pulmonary Sarcoidosis and related diseases.
Lead Product(s): Alidornase alfa
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PRX–110
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Protalix BioTherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 23, 2020